$COR

Camino Minerals' JV Cuprum received DGA authorization to start water works at the Puquios copper project in Chile after posting a $1.7M bond. The bond will be returned post-construction and certification.

Cencora (COR) appointed Robert E. Sanchez as an independent director. The stock is trading at $309, with mixed recent performance: -6.62% over 30 days, +3.52% over 90 days, and +2.86% over one year. Analysts suggest it may be undervalued at a fair value of $369, citing growth in specialty services. However, risks include biosimilar fee pressure and customer contract shifts.

Cencora, Inc. (COR) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Press Release CENCORA ELECTS ROBERT E. SANCHEZ TO ITS BOARD OF DIRECTORS CONSHOHOCKEN, PA, September 25, 2026 — Cencora, Inc. (NYSE: COR) today announced that its Board of Directors has elected Robert E. Sanchez as a new independent director, effective October 1, 202

Cencora (NYSE:COR) reported elevated prescription utilization trends rebounding in March, with most Walgreens business under its primary contract. The company expects accelerating growth in Q4, focusing on oncology and retina specialties. Cencora acquired the remaining interest in OneOncology, citing synergies with Retina Consultants of America. Management discussed biosimilars, policy impacts, and international growth, maintaining capital allocation priorities.

Cencora's CFO Eva Boratto, formerly of Merck and CVS Health, highlighted the company's growth strategy in specialty pharmaceuticals and MSO expansion. She praised the clear strategy and the company's role in the pharmaceutical market. Cencora expects its MSO business to grow, focusing on retina and oncology. The company also discussed its clinical trial support and capital allocation priorities, including investments in MSO platforms and opportunistic share repurchases.

Cencora (COR) reported Q3 revenue of $84.8B (+5.1%) and adjusted EPS of $4.48 (+12.0%). The company raised its full-year adjusted EPS outlook to $17.75-$17.95 and repurchased $1B in stock. Adjusted operating income rose 17.0%, driven by gross profit growth and the OneOncology acquisition. However, operating expenses increased 26.8%, and financing costs rose due to new debt. Lower-margin GLP-1 drugs and lost customers impacted revenue growth.

GREENBERG LON R sold 1,280 shares of Cencora, Inc. (COR) at $321.30 ($0.41M total) on 2026-09-16.

Cencora (COR), a $61.6B pharmaceutical distributor, is down 14% from its 52-week high but up 18.5% over 3 months, outperforming the Dow. Its Q3 revenue missed estimates, but adjusted EPS beat forecasts. Analysts rate it a 'Strong Buy' with a $366.50 target, implying 12.9% upside. Peer Cardinal Health (CAH) gained 60% over the past year.

Cencora's Gregg Gorniak discusses DSCSA compliance investments, emphasizing the need for shared value among supply chain partners. He highlights operational improvements from bundling, but notes adoption depends on mutual economic benefits. Gorniak argues compliance investments must deliver returns across partnerships to drive innovation. His session at HDA’s 2026 Traceability Seminar will outline a framework for strategic growth through compliance.

Cencora (COR) is down 6.7% since reporting Q2 earnings, trading at $97.38. Progyny (PGNY) reported $350.5M revenue, up 5.3% YoY, but missed EBITDA guidance, dropping 14.1% to $25.94. Humana (HUM) reported $40.87B revenue, up 26.2% YoY, beating estimates, and rose 5% to $407.96. Cigna (CI) reported $71.56B revenue, up 6.6% YoY, beating estimates, but fell 4% to $284.64.